InsightsRegulation · Quality · Market

Field notes from inside UK medicinal cannabis & CBD.

Practical regulatory analysis, quality benchmarks and commercial reads — written for founders, operators and investors who need to act on what they read, not just file it away.

Featured·CBD

2026 · 06 · 7 min

Medicexum / Field Notes

UK CBD Novel Foods: ACNFP's Quiet Authority & Operator Oversight

Recent industry chatter around the UK CBD novel foods market highlights persistent anxieties over approval pathways. While much attention focuses on the FSA's public list, the Advisory Committee on Novel Foods and Processes (ACNFP) wields significant, often overlooked, influence. Medicexum clarifies ACNFP's impact on dossier validation and the critical implications for operators.

Read the full piece

MHRA UpdatesFSA Novel FoodsEU GMPICH Q1ABritish PharmacopoeiaHome OfficeACMDACNFPMHRA UpdatesFSA Novel FoodsEU GMPICH Q1ABritish PharmacopoeiaHome OfficeACMDACNFPMHRA UpdatesFSA Novel FoodsEU GMPICH Q1ABritish PharmacopoeiaHome OfficeACMDACNFP

Latest

More from the desk.

Industry2026 · 06

UK Medicinal Cannabis: Prescriber Concentration and Board Oversight

Recent commentary highlights a significant concentration in the UK's medical cannabis prescribing landscape, raising critical questions about system robustness and patient access. This article delves into what this means for operators—from sponsors to responsible persons—and offers practical guidance for navigating regulatory scrutiny and building a resilient, compliant business.

7 min

Market2026 · 06

EU Drug Report's Unseen Impact on UK Medical Cannabis Supply Chains

Medicexum delves into the recently published European Drug Report 2026, exposing how its findings, despite focusing on illicit markets, project significant, yet underestimated, challenges and opportunities for UK legal medical cannabis operators, particularly concerning supply chain resilience and regulatory alignment. We examine the ripple effects for sponsors, Responsible Persons, and ultimately, patients.

7 min

Investment2026 · 06

Medical Cannabis Evidence: Why RCTs Aren't the Whole Picture for UK Investment

Recent commentary from Drug Science unpacks critical flaws in a meta-analysis questioning medicinal cannabis efficacy, highlighting regulators' often-overlooked emphasis on real-world evidence. For UK medicinal cannabis stakeholders, this underscores the nuanced landscape of clinical data and its direct implications for market growth and investment clarity.

7 min

CBD2026 · 05

Medical Cannabis for ADHD: The Nuances of Novel Food Validation

For operators offering CBD products, especially those considering therapeutic claims, understanding the FSA novel food public list and the rigorous ACNFP validation process is critical. The subtle yet crucial distinction between general well-being and specific medical claims, such as for ADHD, continues to challenge the industry.

7 min

Quality2026 · 05

Medical Marijuanas UK: The Stability Data Gap & MHRA Expectations

The UK medical marijuanas sector is maturing, bringing increased scrutiny on product quality lifecycle. MHRA expectations around stability data, while clear in pharmaceutical products, often create a significant practical and financial dilemma for cannabis operators navigating the nuances of ICH Q1A and British Pharmacopoeia monographs.

6 min

Quality2026 · 05

Ensuring Longevity: Stability Programs & Cannabis Long Term Effects

The UK medicinal cannabis sector faces a critical challenge: ensuring product quality and safety over time. While the immediate therapeutic effects are crucial, understanding and mitigating cannabis long term effects on product efficacy and safety through rigorous stability testing is paramount for regulatory compliance and patient trust.

6 min

Compliance2026 · 05

Bona Fide Customer Checks: A GDP Guide for UK Medical Cannabis Wholesalers

How UK medical cannabis wholesalers should verify customer authorisation under EU GDP — practical bona fide checks, evidence, and on-going monitoring that hold up at MHRA inspection.

8 min

Compliance2026 · 05

The Controlled Drugs Register: Record-Keeping for UK Medical Cannabis Wholesalers

A practical guide to maintaining a Misuse of Drugs Regulations 2001 controlled drugs register for medical cannabis — what to record, how to reconcile, and what inspectors actually look for.

9 min

Compliance2026 · 05

Cold Chain and Temperature Mapping for UK Medical Cannabis Storage and Transport

How to design, validate and monitor temperature-controlled storage and transport for UK medical cannabis under EU GDP — mapping, excursions, qualified couriers, and inspection evidence.

9 min

Compliance2026 · 05

MHRA GDP Inspection Readiness: A Practical Guide for Medical Cannabis Wholesalers

How to prepare for an MHRA Good Distribution Practice (GDP) inspection — from documentation and premises to staff competency and CAPA management.

10 min

Compliance2026 · 05

UK Home Office Schedule 2 Controlled Drugs Licence: A Guide for Medical Cannabis Importers

How the Home Office Domestic Schedule 2 Controlled Drugs Licence works for UK medical cannabis importers — eligibility, premises, key personnel, CDLO process, import/export licences and the MHRA WDA(H) interlock.

9 min

Compliance2026 · 05

UK WDA(H) Application Checklist for Medical Cannabis Importers (2026)

A practical, board-level walkthrough of the MHRA Wholesale Dealer's Licence (WDA(H)) application for UK medical cannabis importers — site, RP, QMS, GDP evidence and the Home Office Schedule 2 interlock.

9 min

Regulation2026 · 05

MHRA's Rx-Only Stance: Clarifying CBD Prescriptions in UK Cannabis

A recent MHRA enforcement trend has sent ripples through UK medicinal cannabis clinics and pharmacies: the explicit reinforcement that CBD only preparations, when prescribed as a medicine, fundamentally require a prescription. This isn't groundbreaking, but its emphasis reveals a tightened regulatory focus. For operators, it underlines the critical distinction between novel food CBD and medicinal CBD, and the stringent controls applicable to the latter under the Human Medicines Regulations 2012.

8 min

Investment2026 · 05

UK Medicinal Cannabis Investment: Q2 2026 Regulatory Clarity & Growth

For UK medicinal cannabis investors in 2026, the landscape has significantly shifted. We've moved beyond initial hype, entering a phase of regulatory consolidation and clearer market signals. This article distils the essential insights for those looking to capitalise on a maturing, yet still dynamic, sector, with a focus on investment viability.

8 min

Compliance2026 · 05

MHRA RP Oversight: Unpacking the Board's Duty in UK Medicinal Cannabis

A recent MHRA enforcement action against a licensed medicinal cannabis importer has sent ripples through the sector. While the immediate focus was on GDP lapses and the Responsible Person's (RP) role, a deeper, often overlooked issue arises: the board's ultimate accountability for ensuring effective RP oversight and controlled drug compliance. This isn't just about ticking boxes; it's about embedding a culture of quality from top to bottom.

7 min

CBD2026 · 05

CBD Novel Foods UK: Navigating Validation & the FSA Public List

For UK CBD companies, 2026 continues to be a pivotal year for regulatory compliance. The FSA's Novel Foods Public List remains the gatekeeper for market access, with dossier validation still a significant hurdle. This article delves into the nuances of this process.

7 min

Industry2026 · 05

Navigating UK Medicinal Cannabis GMP Failures: A Board-Level Reckoning

The recent high-profile MHRA enforcement actions against a prominent UK medicinal cannabis operator for serious GMP deviations have sent ripples through the industry. Boards, investors, and founders must now confront what this means for their governance strategies and risk profiles.

7 min

Market2026 · 05

UK Medicinal Cannabis: The Home Office's Unseen Hand in Patient Access

While much focus for UK medicinal cannabis patients rightly centres on clinical guidelines and prescriber education, a less-examined, yet profoundly influential, factor remains the Home Office's regulatory framework. Its remit extends far beyond simply authorising cultivation, subtly, but definitively, shaping the entire supply chain.

6 min

Regulation2026 · 05

Navigating MHRA Enforcement: A 2026 Compass for UK Medicinal Cannabis

As 2026 unfolds, the UK medicinal cannabis and CBD landscapes continue to mature, bringing with them increased regulatory scrutiny. For founders, boards, and investors, understanding the evolving enforcement trends from the MHRA, alongside Home Office licensing nuances and the ACMD's influential stance, isn't just best practice—it's foundational to sustainable operation. This article provides a strategic overview, spotlighting the critical areas demanding attention for robust compliance.

7 min

Quality2026 · 05

Navigating UK Medicinal Cannabis GMP: ICH Q1A and Stability Testing

As the UK medicinal cannabis sector matures into late 2026, the bedrock of compliance remains robust manufacturing and robust data. This article drills down into GMP, specifically focusing on the critical role of ICH Q1A guidelines and stability testing in ensuring product quality and regulatory adherence. Navigating MHRA and Home Office expectations requires deep understanding.

7 min

Compliance2026 · 05

Navigating MHRA Responsible Person Duties in UK Cannabis: 2026 Insights

For UK medicinal cannabis and CBD businesses, the regulatory landscape shifts constantly. By late 2026, understanding the nuances of MHRA Responsible Person duties, robust controlled drug compliance, and effective GDP audit preparation will be paramount for securing and maintaining crucial licences.

7 min

Industry2026 · 05

Navigating the UK Medicinal Cannabis Scale-Up: 2026 Restructuring Imperatives

As 2026 draws to a close, the UK medicinal cannabis and CBD novel foods sectors stand at a critical juncture. Early pioneers have navigated the initial regulatory labyrinths, but sustained growth demands a new level of operational sophistication and strategic restructuring. This piece delves into the shifts reshaping the landscape.

7 min

Compliance2025 · 02

How to Become a Responsible Person (RP) in the UK Medical Cannabis Industry

A step-by-step guide to qualifying as a Responsible Person under MHRA and GDP — covering training, licensing and the operational expectations regulators look for.

8 minUpdated 2026 · 05

Industry2025 · 02

How Media Bias is Holding Back the Cannabis Industry

Why public perception remains a hurdle for medicinal cannabis — and what operators can do to counter outdated narratives in the press.

5 minUpdated 2026 · 05

Regulation2025 · 02

The Importance of MHRA Compliance for UK Medical Cannabis Brands

Scrutiny of medicinal cannabis advertising and promotion is rising. Compliance with MHRA's Blue Guide is now a commercial differentiator.

6 minUpdated 2026 · 05

Market2025 · 02

The Global Cannabis Market 2024: Key Insights & Trends

Legalisation, market expansion and patient access — the global picture and what it means for UK operators and investors.

7 minUpdated 2026 · 05

Investment2025 · 02

Why Now is the Best Time to Invest in the UK Medical Cannabis Market

Rapid growth, regulatory clarity and investor appetite are converging — a practical look at where capital is flowing in UK medical cannabis.

6 minUpdated 2026 · 05

Quality2025 · 02

UK Medical Cannabis Stability Testing: ICH Guidelines & Compliance

Stability studies, ICH alignment and British Pharmacopoeia obligations — what UK medical cannabis operators must demonstrate to stay compliant.

7 minUpdated 2026 · 05

Briefing

Get our regulatory & commercial briefings before they're public.

Short, signal-only updates for founders, boards and investors operating in UK medicinal cannabis and CBD novel foods.

Request the briefing